Back to search

Peptide record

TPDB11019

S-24-R2PLx Antibacterial Anticancer Antifungal Toxicity standard

28 amino acids

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB11019

Peptide_Name

S-24-R2PLx

Activity

Antibacterial Anticancer Antifungal Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides

Database_Source

AntiBP3 Peptipedia CancerPPD 2.0 dbACP Antifungipept CAFPdb dbAMP

Sequence_Type

standard

Has_Modification No

Description A 28-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, Peptipedia, CancerPPD 2.0, and other sources, with an available 3D structural model.

Sequence

GIMDTVKNAAKNLAGQLLDKLKCSITAC

FASTA

>TPDB11019|Antibacterial;Anticancer;Antifungal;Toxicity|length=28
GIMDTVKNAAKNLAGQLLDKLKCSITAC

Formula C124H219N35O39S3

Absent Amino Acids REHFPWY

Common Amino Acids ALK

Mass 2920.49

PI 9.05

Basic Residues 4

Acidic Residues 2

Hydrophobic Residues 12

Net Charge +2

Boman Index 4.09

Hydrophobicity 0.229

Aliphatic Index 108.21

Half Life

Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour

Extinction Coefficient Cystines 125

Absorbance 280nm 4.28

Polar Residues 8

number

Amino Acid Distribution

A: 4 R: 0 N: 2 D: 2 C: 2 E: 0 Q: 1 G: 2 H: 0 I: 2 L: 4 K: 4 M: 1 F: 0 P: 0 S: 1 T: 2 W: 0 Y: 0 V: 1

Length

Formula

C124H219N35O39S3

Mass

2920.49

9.05

Net Charge

Boman Index

4.09

Hydrophobicity

0.229

C_terminal_Modification

Free

Chirality

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Synthetic Analogue of Ranatuerin-2PLx

Evidence 1 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 32 µM

Target

Target Organism Staphylococcus aureus NCTC 10788

Source & Reference

Database Source dbAMP

Other

Source Activity Label	Source Definition
Antibacterial	dbAMP classified as Antibacterial under the Anti-bacterial function class.

Evidence Text

Active against S. aureus NCTC 10788 (MIC 32 uM) and E. coli NCTC 10418 (MIC 32 uM). Inactive: C.albicans NCTC 1467 (MIC 256 uM), MRSA ATC

Evidence 2 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 32 µM

Target

Target Organism Escherichia coli NCTC 10418

Source & Reference

Database Source dbAMP

Other

Evidence Text

Active against S. aureus NCTC 10788 (MIC 32 uM) and E. coli NCTC 10418 (MIC 32 uM). Inactive: C.albicans NCTC 1467 (MIC 256 uM), MRSA ATCC 12493 (MIC 256 uM) (MRSA-inactive

Evidence 3 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 256 µM

Target

Target Organism C.albicans NCTC 1467

Source & Reference

Database Source dbAMP

Other

Evidence Text

ve against S. aureus NCTC 10788 (MIC 32 uM) and E. coli NCTC 10418 (MIC 32 uM). Inactive: C.albicans NCTC 1467 (MIC 256 uM), MRSA ATCC 12493 (MIC 256 uM) (MRSA-inactive), E.fecalis NCTC 12697 (MIC 128 uM), and P.a

Evidence 4 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement 128 µM

Target

Target Organism E.fecalis NCTC 12697

Source & Reference

Database Source dbAMP

Other

Evidence Text

nactive: C.albicans NCTC 1467 (MIC 256 uM), MRSA ATCC 12493 (MIC 256 uM) (MRSA-inactive), E.fecalis NCTC 12697 (MIC 128 uM), and P.aeruginosa ATCC 27853 (MIC >512 uM).

Evidence 5 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antibacterial

Activity Measurement >512 µM

Target

Target Organism P.aeruginosa ATCC 27853

Source & Reference

Database Source dbAMP

Other

Evidence Text

uM), MRSA ATCC 12493 (MIC 256 uM) (MRSA-inactive), E.fecalis NCTC 12697 (MIC 128 uM), and P.aeruginosa ATCC 27853 (MIC >512 uM).

Evidence 6 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 792.60 µM

Detail Source Activity Anticancer

Activity Measurement 792.60 µM

Target

Cancer Type Prostate Cancer

Cell Line PC-3

Tissue Affected Prostate

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 7 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 58.18 µM

Detail Source Activity Anticancer

Activity Measurement 58.18 µM

Target

Cancer Type Lung Cancer

Cell Line H-157

Tissue Affected Lung

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 8 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 179.00 µM

Detail Source Activity Anticancer

Activity Measurement 179.00 µM

Target

Cancer Type Skin Cancer

Cell Line MDA-MB-435S

Tissue Affected Skin

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 9 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 278.30 µM

Detail Source Activity Anticancer

Activity Measurement 278.30 µM

Target

Cancer Type Brain Tumor

Cell Line U-251-MG

Tissue Affected Brain

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 10 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 316.90 µM

Detail Source Activity Anticancer

Activity Measurement 316.90 µM

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2018

Evidence 11 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 32 µM

Target

Target Organism Staphylococcus aureus NCTC 10788

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Source Activity Label	Source Definition
Antifungal	dbAMP classified under the Anti-fungal function class.

Evidence Text

Active against S. aureus NCTC 10788 (MIC 32 uM) and E. coli NCTC 10418 (MIC 32 uM). Inactive: C.albicans NCTC 1467 (MIC 256 uM), MRSA ATC

Evidence 12 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 32 µM

Target

Target Organism Escherichia coli NCTC 10418

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

Active against S. aureus NCTC 10788 (MIC 32 uM) and E. coli NCTC 10418 (MIC 32 uM). Inactive: C.albicans NCTC 1467 (MIC 256 uM), MRSA ATCC 12493 (MIC 256 uM) (MRSA-inactive

Evidence 13 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 256 µM

Target

Target Organism C.albicans NCTC 1467

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

Evidence 14 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement 128 µM

Target

Target Organism E.fecalis NCTC 12697

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

nactive: C.albicans NCTC 1467 (MIC 256 uM), MRSA ATCC 12493 (MIC 256 uM) (MRSA-inactive), E.fecalis NCTC 12697 (MIC 128 uM), and P.aeruginosa ATCC 27853 (MIC >512 uM).

Evidence 15 Activity

Activity

Activity Endpoint MIC

Detail Source Activity Antifungal

Activity Measurement >512 µM

Target

Target Organism P.aeruginosa ATCC 27853

Source & Reference

Database Source dbAMP CAFPdb Antifungipept

Other

Evidence Text

uM), MRSA ATCC 12493 (MIC 256 uM) (MRSA-inactive), E.fecalis NCTC 12697 (MIC 128 uM), and P.aeruginosa ATCC 27853 (MIC >512 uM).

Evidence 16 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 1185.00 µM

Toxicity Type Cytotoxic

Toxicity Raw

IC50 | 1185.00 | µM | target cell: Human microvascular endothelial cells HMEC-1

Target

Target Cell Human microvascular endothelial cells HMEC-1

Source & Reference

Database Source NA

Source Database DBAASP

Reference

A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018

Evidence 17 Activity

Activity

Activity Endpoint 7% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 512 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

7% Hemolysis | 512 | µM | target cell: Horse erythrocytes

Target

Target Cell Horse erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018

Evidence 18 Activity

Activity

Activity Endpoint <5% Hemolysis

Detail Source Activity Toxicity

Activity Measurement 256 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

<5% Hemolysis | 256 | µM | target cell: Horse erythrocytes

Target

Target Cell Horse erythrocytes

Source & Reference

Database Source NA

Source Database DBAASP

Reference

A novel antimicrobial peptide, Ranatuerin-2PLx, showing therapeutic potential in inhibiting proliferation of cancer cells | Biosci Rep | 2018

Evidence 19 Activity

Activity

Activity Endpoint IC50

Detail Source Activity Toxicity

Activity Measurement 1185.00 µM

Toxicity Type Hemolytic Cytotoxic

Toxicity Raw

Hemolytic_activity: Horse erythrocytes: Low haemolytic activity | Cytotoxicity: HMEC-1: IC50=1185.00 µM

Target

Target Cell erythrocytes

Source & Reference

Database Source NA

Source Database DRAMP

Reference

Biosci Rep. 2018 Nov 9 38(6):BSR20180710.